Foghorn Therapeutics Inc.
FHTX
$6.26
-$0.23-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 14.35% | 6.36% | 14.24% | 20.94% | 12.78% |
| Total Depreciation and Amortization | -33.10% | -11.86% | 6.79% | 2.49% | -5.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.20% | 11.18% | 10.63% | -26.08% | -36.77% |
| Change in Net Operating Assets | -20.82% | 3.89% | 0.39% | 1.01% | 33.50% |
| Cash from Operations | 6.91% | 8.03% | 14.25% | 14.58% | 17.46% |
| Capital Expenditure | 94.03% | 97.36% | 94.48% | -14.01% | -253.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.46% | 342.64% | 486.54% | 947.88% | -70.59% |
| Cash from Investing | 16.14% | 335.23% | 474.67% | 917.68% | -71.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,659.90% | -51.45% | -99.04% | -99.58% | -98.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 11.03% | 45.98% | -- | 100.00% | -100.00% |
| Cash from Financing | 3,379.28% | -51.48% | -99.03% | -99.58% | -98.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.14% | 254.60% | 208.37% | 362.89% | -179.80% |